United States Patent 4,818,538: Scope, Claims, Expiration, and Zidovudine Patent Landscape

U.S. Patent 4,818,538 protected pharmaceutical dosage forms containing 3'-azido-3'-deoxythymidine, now known as zidovudine or AZT. Its claims covered solid and liquid unit doses, sterile parenteral compositions, suppositories, suspensions, and compositions containing AZT phosphate metabolites. The patent issued on April 4, 1989, and its original pre-URAA term expired on April 4, 2006. It is no longer an enforceable patent and does not create current U.S. generic-entry risk.

What does U.S. Patent 4,818,538 protect?

The patent protects pharmaceutical compositions and packaged dosage forms, not zidovudine as a chemical compound in every context.

Its central limitations are:

The active ingredient is AZT, a pharmaceutically acceptable AZT salt, or an AZT phosphate derivative.
Many claims require a dose of 5 to 500 mg per dosage unit.
The composition must contain a pharmaceutically acceptable solid or liquid carrier.
Certain claims require a sealed container.
Certain claims require sterility and parenteral administration.
Dependent claims cover suspensions and suppositories.

The patent is therefore a formulation and dosage-form patent. A product could infringe only if it satisfied every limitation of an asserted claim. Selling zidovudine alone, without practicing a claimed dosage-form limitation, would not necessarily infringe this patent.

The patent does not expressly claim:

AZT as a chemical compound in the abstract;
a method of treating HIV or AIDS;
a specific dosing schedule;
a particular tablet excipient;
a specific tablet coating;
a specific capsule shell;
a manufacturing process;
a polymorph or crystalline form;
a particular brand or package configuration;
combination therapy with another antiretroviral.

How do the individual claims of Patent 4,818,538 operate?

Claim	Principal subject matter	Key limitations	Practical scope
1	Sealed solid dosage product	Sealed container; unit dosage; 5-500 mg AZT; solid carrier	Tablets, capsules, powders, or similar packaged solid doses
2	Liquid dose	5-500 mg AZT or salt; liquid carrier	Liquid oral or other liquid dosage forms; no express sealed-container requirement
3	Sterile parenteral product	Sealed container; sterile composition; liquid carrier; AZT or salt	Injectable or infusion products
4	Unit dosage containing AZT salt	5-500 mg per unit; solid or liquid carrier	Salt-based tablets, capsules, solutions, or other unit doses
5	Unit dosage containing AZT 5'-monophosphate	5-500 mg; salt permitted; solid or liquid carrier	Formulations of AZT-MP
6	Unit dosage containing AZT 5'-diphosphate	5-500 mg; salt permitted; solid or liquid carrier	Formulations of AZT-DP
7	Unit dosage containing AZT 5'-triphosphate	5-500 mg; salt permitted; solid or liquid carrier	Formulations of AZT-TP
8	Suspension	Depends on claims 2, 4, 5, 6, or 7	Liquid suspension versions of the listed compositions
9	Suppository	Depends on claims 1, 4, 5, 6, or 7	Solid suppository versions of the listed compositions

What does claim 1 cover?

Claim 1 requires a sealed container containing a pharmaceutical composition in unit dosage form. The composition must contain 5 to 500 mg of AZT and a pharmaceutically acceptable solid carrier.

The claim is directed to a packaged solid dosage unit. A conventional zidovudine tablet or capsule in a sealed commercial package could have fallen within the literal scope during the patent term if the dosage contained between 5 and 500 mg of AZT and included a solid carrier.

The 5 mg and 500 mg boundaries matter. A dosage below 5 mg or above 500 mg would not satisfy the stated numerical range, subject to any applicable doctrine-of-equivalents analysis. The sealed-container limitation also narrows the claim compared with an unrestricted composition claim.

What does claim 2 cover?

Claim 2 covers a dose of AZT or a pharmaceutically acceptable AZT salt with a pharmaceutically acceptable liquid carrier. It does not expressly require a sealed container or a unit dosage form.

The claim could reach liquid solutions and other liquid preparations, including oral liquids and potentially nonparenteral liquid products, provided the product contains 5 to 500 mg of active ingredient per dose.

The term “dose” creates a dosage-unit limitation, but the claim does not define the volume, concentration, route of administration, or excipient system.

What does claim 3 cover?

Claim 3 covers a sealed container containing a sterile pharmaceutical composition for parenteral administration. The composition must include a pharmaceutically acceptable liquid carrier and AZT or an AZT salt.

Unlike claims 1, 2, and 4-7, claim 3 does not recite the 5 to 500 mg dosage range. Its principal limitations are:

sealed container;
sterile composition;
parenteral administration;
liquid carrier; and
AZT or an acceptable salt.

This claim was potentially relevant to injectable AZT products, including sterile solutions in vials, ampoules, or infusion containers. It does not require a particular concentration or injection device.

What do claims 4 through 7 cover?

Claim 4 covers unit dosage compositions containing 5 to 500 mg of a pharmaceutically acceptable AZT salt. The carrier may be solid or liquid.

Claims 5, 6, and 7 extend the formulation concept to the phosphorylated forms of AZT:

5'-monophosphate;
5'-diphosphate; and
5'-triphosphate.

These claims are materially different from ordinary zidovudine tablet claims. They do not merely cover AZT formulations. They cover dosage forms containing AZT phosphate derivatives or their pharmaceutically acceptable salts.

The inclusion of AZT-MP, AZT-DP, and AZT-TP broadens the chemical subject matter but does not necessarily translate into equivalent commercial value. Zidovudine is administered as the nucleoside. Its active triphosphate metabolite is formed intracellularly. Commercial products have historically centered on zidovudine rather than on an administered AZT triphosphate product. The phosphate claims therefore appear more relevant to claim breadth and defensive coverage than to the principal Retrovir commercial product.

What formulations are protected by U.S. Patent 4,818,538?

The patent reaches several formulation categories.

Solid oral dosage forms

Claims 1, 4, 5, 6, 7, and 9 can implicate solid dosage products. Potential examples include:

tablets;
capsules;
powders;
granules;
compressed dosage units; and
suppositories.

Claim 1 is narrower because it requires a sealed container and AZT, rather than an AZT salt or phosphate derivative. Claims 4-7 are broader as to carrier form but narrower as to the specified active chemical form.

Liquid formulations

Claims 2 and 4-7 cover liquid-carrier compositions. Claim 8 specifically adds suspension formulations.

Potential products include:

oral solutions;
oral suspensions;
injectable solutions;
infusion formulations; and
liquid dosage units containing an AZT salt or phosphate derivative.

Claim 3 is the principal parenteral claim because it expressly requires sterility, a sealed container, and parenteral administration.

Suppositories

Claim 9 covers suppository forms of the compositions identified in claims 1 and 4-7. This claim requires the product to fall within one of those underlying claims and to be in suppository form.

The suppository claim does not independently cover every AZT suppository. The underlying active-ingredient, dosage, carrier, and dosage-form limitations remain relevant.

When did U.S. Patent 4,818,538 expire?

Event	Date
Patent issued	April 4, 1989
Original pre-URAA patent term	17 years from issue
Expected statutory expiration	April 4, 2006
Current status	Expired
Current enforceability	None

Patent 4,818,538 was issued before the Uruguay Round Agreements Act changed the standard U.S. patent term to 20 years from the earliest effective nonprovisional filing date. Pre-URAA patents generally retained a 17-year term from issuance, subject to applicable terminal disclaimers, reexaminations, extensions, or other term adjustments. Public patent records identify the patent as expired by its ordinary term. (U.S. Patent and Trademark Office, 1989)

The expiration date means that the claims cannot support a present-day U.S. infringement action. The patent may remain relevant for historical freedom-to-operate analysis, prosecution history, prior-art review, and valuation of the original zidovudine franchise.

What was the relationship between Patent 4,818,538 and the AZT compound patents?

The principal distinction is between compound protection and formulation protection.

Protection category	Representative subject matter	Business effect
Compound patent	AZT chemical compound and related antiviral subject matter	Broadest historical control over the active pharmaceutical ingredient
Formulation patent	AZT dosage forms, carriers, containers, sterility, suspensions, and suppositories	Product-specific protection for pharmaceutical presentations
Regulatory exclusivity	FDA approval and associated exclusivity periods	Delayed reliance on the reference product, independent of patent scope
Manufacturing patents	Synthesis, purification, crystallization, or process controls	Potential barriers to producing the active or dosage form

U.S. Patent 4,724,232 is commonly identified with the earlier AZT compound and antiviral patent estate. Patent 4,818,538 addressed pharmaceutical compositions and dosage forms. The two patents should not be treated as interchangeable. A formulation patent can expire later than a compound patent, but it does not recreate compound-level exclusivity after the compound patent expires.

What was the FDA and Orange Book status of zidovudine?

Zidovudine was approved by the FDA as Retrovir, marketed by Burroughs Wellcome, for HIV-related indications. FDA approval occurred in 1987, and the product was later approved in multiple dosage forms, including capsules, oral solution, and intravenous injection. (U.S. Food and Drug Administration, 1987; U.S. Food and Drug Administration, 2024)

The historical Orange Book listing is relevant because it identifies patents submitted by the NDA holder for approved drug products. Patent 4,818,538 was associated with the historical AZT product estate, but its expiration in 2006 removed it as a live patent barrier. Current Orange Book listings should be evaluated by product and NDA, not by the existence of the old patent record alone. (U.S. Food and Drug Administration, 2025)

Did Patent 4,818,538 create Paragraph IV risk?

During its term, an ANDA applicant seeking approval for a product that could practice the listed claims could have faced a Paragraph IV certification issue. The relevant analysis would have depended on:

the specific FDA-listed reference product;
whether the patent was listed for the relevant dosage form;
the applicant’s proposed strength;
whether the product used a solid or liquid carrier;
whether the product was sterile and parenteral;
whether the product was a suspension or suppository; and
whether the patent remained unexpired when the ANDA was submitted.

Today, Patent 4,818,538 cannot generate a new patent-based Paragraph IV litigation threat because it has expired. Generic applicants may rely on the ordinary ANDA pathway without designing around this patent.

Which companies challenged or competed against the AZT franchise?

The main competitive transition occurred after the original patent and regulatory exclusivity periods ended. Generic zidovudine products entered the U.S. market from multiple manufacturers, including companies that received FDA approval for capsules, oral solution, or injectable products.

The competitive landscape included:

Burroughs Wellcome, later part of Glaxo Wellcome and GlaxoSmithKline;
generic manufacturers supplying zidovudine capsules and oral solution;
combination-product manufacturers selling zidovudine with other antiretrovirals; and
manufacturers of fixed-dose antiretroviral combinations containing zidovudine and lamivudine.

The relevant commercial competition shifted from patent exclusivity to manufacturing cost, regulatory approval, supply reliability, hospital contracting, and combination-antiretroviral adoption.

No biosimilar pathway applies to zidovudine. Zidovudine is a chemically synthesized small molecule, so competitive products are generics rather than biosimilars.

Were there licensing deals involving AZT?

The historical AZT commercialization structure involved government-sponsored research and licensing to Burroughs Wellcome. The National Cancer Institute and the National Institutes of Health played a central role in the development and clinical evaluation of AZT. Burroughs Wellcome obtained commercial rights and developed Retrovir for FDA approval. (National Institutes of Health, 2020)

The licensing history is important for understanding ownership and commercialization, but it does not extend the term of Patent 4,818,538. A license cannot preserve an expired patent claim as an enforceable exclusion right.

What patent litigation affected zidovudine?

The major historical disputes surrounding AZT included questions about inventorship, patent ownership, government involvement, licensing, royalties, and the allocation of credit for discovery and development. Those disputes concerned the broader AZT patent and commercialization program, not only the formulation claims of Patent 4,818,538.

There is no continuing litigation risk from Patent 4,818,538 because the patent expired in 2006. Any historical infringement action based solely on this patent would be subject to expiration, statute-of-limitations rules, laches and other equitable doctrines, and the specific dates of the alleged conduct.

A present-day competitor should focus on:

active patents covering a new formulation;
combination products;
controlled-release dosage forms;
taste-masked oral liquids;
injectable stability systems;
manufacturing processes; and
trademarks or regulatory exclusivity.

How strong was the patent estate for zidovudine?

The estate was historically strong at the compound level but narrower at the formulation level.

Strengths of Patent 4,818,538

It covered multiple dosage forms.
It included both AZT and pharmaceutically acceptable salts.
It addressed solid and liquid carriers.
It separately covered sterile parenteral products.
It included suspensions and suppositories.
The 5-500 mg range captured common therapeutic dosage strengths.

Limitations of Patent 4,818,538

It did not claim AZT as a chemical compound without formulation limitations.
Several claims required a defined dosage range.
Claims 1 and 3 required a sealed container.
Claim 3 required sterility and parenteral administration.
Claims 5-7 focused on phosphate derivatives with limited historical commercial relevance.
The patent did not cover all methods of using zidovudine.
The patent expired in 2006.

The formulation patent was therefore commercially meaningful while active, but it did not provide a durable replacement for the earlier compound patent.

What generic launch scenarios existed?

A generic applicant during the patent term could have pursued several strategies:

Wait for patent expiration and file or maintain an ANDA based on paragraph III certification.
Challenge the patent under Paragraph IV if the listed claims were believed invalid, unenforceable, or not infringed.
Design around the claims by using a dosage outside the stated range, where clinically and regulatorily acceptable.
Avoid a sealed-container limitation where the product and distribution model allowed it.
Develop a formulation that did not meet the claimed active-ingredient or carrier limitations.
Seek approval for a dosage form not covered by the applicable Orange Book listing.

After April 4, 2006, the patent ceased to be a meaningful launch constraint. The commercial barriers became FDA approval, API sourcing, quality control, manufacturing economics, and market demand.

What geographic coverage did the patent have?

U.S. Patent 4,818,538 had territorial effect only in the United States. It did not directly block products made, sold, or imported outside the United States unless another legal right applied.

Foreign counterparts, if granted, required separate analysis by country. Relevant differences could include:

distinct claim language;
different priority treatment;
national-phase prosecution;
patent-term rules;
supplementary protection certificates;
compulsory licensing;
national litigation; and
different FDA-equivalent regulatory regimes.

A U.S. freedom-to-operate conclusion cannot be exported automatically to Europe, Canada, Japan, or other jurisdictions.

What manufacturing and intellectual-property barriers remain for zidovudine?

Patent 4,818,538 no longer creates a manufacturing barrier. Current barriers may still arise from:

API quality specifications;
impurity and residual-solvent controls;
sterile manufacturing requirements for injectable products;
stability of liquid formulations;
container-closure integrity;
validated analytical methods;
supply-chain qualification;
facility compliance with current good manufacturing practices;
active patents on new combinations or delivery systems; and
regulatory requirements for ANDA or other abbreviated approvals.

These are operational and regulatory barriers, not surviving exclusivity under Patent 4,818,538.

Key Takeaways

U.S. Patent 4,818,538 is a historical zidovudine formulation patent.
It covers unit doses, solid and liquid carriers, sterile parenteral compositions, suspensions, suppositories, and AZT phosphate derivatives.
Claims 1-4 principally address AZT and its salts.
Claims 5-7 address the mono-, di-, and triphosphate forms.
The patent does not claim AZT as a chemical compound without dosage-form limitations.
The patent issued on April 4, 1989.
Its ordinary patent term expired on April 4, 2006.
It cannot create current U.S. Paragraph IV, infringement, or generic-launch risk.
Zidovudine is a small-molecule drug, so biosimilar analysis does not apply.
Current commercial barriers relate to FDA approval, manufacturing, supply, and any later patents on combinations or new delivery technologies.

FAQs

Does Patent 4,818,538 cover Retrovir tablets?

Historically, it could have covered Retrovir tablets within the claimed dosage range and carrier limitations, particularly under claims 1 or 4. It no longer blocks Retrovir or generic zidovudine tablets because the patent expired.

Does Patent 4,818,538 cover zidovudine oral solution?

Claims 2 and 4 could reach liquid dosage products containing the specified quantity of AZT or an acceptable salt with a liquid carrier. The patent is expired.

Does Patent 4,818,538 cover AZT triphosphate?

Claim 7 expressly addresses unit dosage compositions containing 5 to 500 mg of AZT 5'-triphosphate or an acceptable salt. The claim is directed to a pharmaceutical composition, not merely the intracellular formation of AZT triphosphate after administration of zidovudine.

Can a company still sue over Patent 4,818,538?

The patent cannot support a prospective U.S. infringement claim because it expired in 2006. Historical claims would face separate limitations, timeliness, and proof issues.

Is zidovudine still protected by active patents?

The original AZT patent estate is expired. A current product could still implicate later patents covering a particular fixed-dose combination, formulation, manufacturing process, delivery system, or new use, but those rights would require separate patent-by-patent review.

References

U.S. Food and Drug Administration. (1987). Retrovir (zidovudine) approval history and prescribing information. FDA.
U.S. Food and Drug Administration. (2024). Retrovir (zidovudine) prescribing information. FDA.
U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
U.S. National Institutes of Health. (2020). Zidovudine, HIV research, and the development of antiretroviral therapy. NIH.
U.S. Patent and Trademark Office. (1989). U.S. Patent No. 4,818,538, Pharmaceutical compositions. USPTO.
U.S. Patent and Trademark Office. (1988). U.S. Patent No. 4,724,232, 3'-Azido-3'-deoxythymidine and pharmaceutical uses. USPTO.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	8506869	Mar 16, 1985
United Kingdom	8511774	May 09, 1985

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
African Regional IP Organization (ARIPO)	11	⤷ Start Trial
African Regional IP Organization (ARIPO)	8600027	⤷ Start Trial
African Regional IP Organization (ARIPO)	8600044	⤷ Start Trial
African Regional IP Organization (ARIPO)	90	⤷ Start Trial
Austria	113603	⤷ Start Trial
Austria	135011	⤷ Start Trial
Austria	190064	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 4,818,538

Summary for Patent: 4,818,538